Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837999 | 0.92 | MAPT (0.61) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL30002204 | 0.92 | MAPT (0.61) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL2841013 | 0.92 | MAPT (0.67) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL18582699 | 0.92 | MAPT (0.67) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL42982 | 0.92 | MAPT (0.67) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL39153 | 0.89 | ALOX15 (0.49) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL17262425 | 0.89 | ALOX15 (0.49) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL2835206 | 0.89 | ALOX15 (0.49) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL18582451 | 0.87 | MAPT (0.56) | MAPTALOX15LMNATSHRHIF1A | |
| SCHEMBL40179 | 0.87 | MAPT (0.56) | MAPTALOX15LMNATSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| US-7763649-B2 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2174658-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7521584-B2 | Carotenoid analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1982711-A1 | Compositions comprsing nebivolol | MYLAN LABORATORIES, INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20050113372-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20050090469-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMA, INC. | 2005-04-28 | — | — | US | disclosed |
| US-20050075316-A1 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050065096-A1 | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMA, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CPT1A, TXNRD2, PC | MAPT 4758/4885ALOX15 29/4885LMNA 1111/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | MAPT 4813/4885ALOX15 194/4885LMNA 29/4885 |
| US-20050065096-A1 | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CYP11B2, CYP11B1, PTGER1 | MAPT 3845/4885ALOX15 11/4885LMNA 969/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | MAPT 3997/4885ALOX15 45/4885LMNA 2708/4885 |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | MAPT 3961/4885ALOX15 86/4885LMNA 716/4885 |
| US-20050090469-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | MAPT 3788/4885ALOX15 55/4885LMNA 1146/4885 |
| US-20050075316-A1 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CYP11B2, CYP11B1, PTGER1 | MAPT 3844/4885ALOX15 5/4885LMNA 1276/4885 |
| US-20050113372-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of disease | NOS1, NOS2, NOS3 | MAPT 4175/4885ALOX15 9/4885LMNA 992/4885 |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | MAPT 1406/4885ALOX15 811/4885LMNA 862/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | MAPT 4360/4885ALOX15 18/4885LMNA 685/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | MAPT 3908/4885ALOX15 51/4885LMNA 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.